Obinutuzumab

A4DAB184 | Cancer | Approved
MS4A1/CD20
G1 / IgG1
GLYCART Biotechnology Biogen Idec Chugai Pharmaceutical Dana-Farber Cancer Institute Genentech Lymphoma Academic Research Organisation Nippon Shinyaku OHSU Knight Cancer Institute Pharmacyclics Polish Myeloma Consortium Roche Thomas Jefferson University University of Heidelberg University of Leeds
Approved
Whole mAb
Afutuzumab GA-101 GA101 GA 101 Gazyva Gazyvaro R-7159 R 7159 R7159 RG 7195 RG-7159 RG7159 RO-5072759 RO5072759 RO 5972759
6
IMGT PubChem (135332744) PubChem (160682610) PubChem (178103523) PubChem (347910388) PubChem (384647096) PubChem (385327553) PubChem (387060188) PubChem (440798422) PubChem (459140318) PubChem (472264655) PubChem (472422594) PubChem (481101766) PubChem (481155382) PubChem (488412712) PubChem (498123658) PubChem (513905828) Thera-SAbDab YAbS
Avg A4D Score
-0.6898
Score Range
-0.72 to -0.62
Structures
5
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB184_3pp4_H_L 3pp4 100% -0.7056 6.5 9.0 -0.3047 -0.759
A4DAB184_3pp3_I_K 3pp3 100% -0.6911 6.5 4.0 -0.2801 -0.7452
A4DAB184_6y97_H_L 6y97 100% -0.62 7.0 4.0 -0.2052 -0.7409
A4DAB184_6y9a_H_L 6y9a 100% -0.7177 6.5 4.0 -0.1953 -0.7867
A4DAB184_3pp3_H_L 3pp3 100% -0.7144 6.5 9.0 -0.2957 -0.7694